Literature DB >> 10194527

Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma.

M Klein1, E Picard, J M Vignaud, B Marie, L Bresler, B Toussaint, G Weryha, A Duprez, J Leclère.   

Abstract

Angiogenesis is implicated in several pathological conditions, such as inflammation and tumor growth. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is a potent stimulator of endothelial cell proliferation in vitro and in vivo. The present work aimed to compare VEGF expression in human normal thyroid glands, thyroiditis tissue and thyroid carcinomas using immunohistochemistry and in situ hybridization (ISH). Both chronic lymphocytic thyroiditis and differentiated thyroid carcinomas were found to strongly express VEGF mRNA and encode larger amounts of VEGF than normal thyroid tissue as attested by a VEGF immunostaining score. In addition, tumor samples from patients with metastases showed a higher immunostaining score than their non-metastatic counterparts (P<0.05). Carcinomas with the greatest contents of VEGF mRNA and VEGF protein had the most intense mitogenic activity. Special focus on endothelial cells showed intense mitogenic activity in neoplastic tissues in contrast to the total quiescence of endothelial cells in non-tumoral tissues. An intense VEGF production by differentiated thyroid carcinoma, attested either by a higher immunostaining score or a strong VEGF mRNA expression using ISH, could be a promising marker of tumor aggressiveness and may also be useful as a predictor of metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194527     DOI: 10.1677/joe.0.1610041

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  37 in total

1.  Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.

Authors:  Eric J Sherman; Lara A Dunn; Heiko Schöder; Alan L Ho; Shrujal S Baxi; Ronald A Ghossein; Sofia S Haque; Cami Sima; Robert Michael Tuttle; David G Pfister
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

2.  A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.

Authors:  E E W Cohen; M Tortorici; S Kim; A Ingrosso; Y K Pithavala; P Bycott
Journal:  Cancer Chemother Pharmacol       Date:  2014-10-15       Impact factor: 3.333

3.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

4.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

5.  VEGF and GM-CSF levels in nodular thyroid diseases.

Authors:  Birsen Bilgici; Gulcin C Ecemis; Ozgur K Tuncel; Ilkay K Bayrak; Elif K Kan; Aysegul Atmaca
Journal:  Endocrine       Date:  2013-04-28       Impact factor: 3.633

6.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

7.  The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.

Authors:  Joanna Klubo-Gwiezdzinska; Roman Junik; Ewa Kopczynska; Olga Juraniec; Hanna Kardymowicz
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

8.  Autophagy: A potential target for thyroid cancer therapy (Review).

Authors:  Heqing Yi; Bin Long; Xuemei Ye; Lijun Zhang; Xiaodong Liu; Chunyan Zhang
Journal:  Mol Clin Oncol       Date:  2014-06-06

9.  Clinical significance of osteopontin expression in cervical cancer.

Authors:  HanByoul Cho; Soon Won Hong; Youn Jin Oh; Min A Kim; Eun Suk Kang; Jong Min Lee; Sang Wun Kim; Sung Hoon Kim; Jae Hoon Kim; Young Tae Kim; Kook Lee
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-22       Impact factor: 4.553

10.  Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.

Authors:  Ronan J Kelly; Olivier Rixe
Journal:  Target Oncol       Date:  2009-10-30       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.